Compare the measured outcomes
Healthy volunteers, men in a hair trial, rats and excised skin enter the evidence in different ways. Compare the study populations before generalising a result.
Human study preparations
| Preparation studied | Human evidence described here |
|---|---|
| BPC-157 | Three small pilot studies counted in a 2025 review |
| Full-length thymosin beta-4 | Placebo-controlled Phase 1 IV safety study in 40 healthy volunteers |
| Topical GHK-Cu | Small skin studies summarised in reviews |
| Topical 5-aminolevulinic acid + GHK | 6-month hair trial in 45 men |
I would resist sorting those rows into a league table. They ask different questions: tolerability in healthy people, reports from small clinical pilots, or particular skin and hair outcomes. A larger sample can still be the wrong evidence for a claim if it tested a different substance or endpoint.
The 40-volunteer study belongs in the full-length thymosin beta-4 row, however often it is mentioned beside TB-500.
Cells, animals and excised tissue
| Experimental setting | What was measured |
|---|---|
| BPC-157 in rats | Ulcer formation and rebuilding of the gastric lining |
| Full-length thymosin beta-4 in rats | Neurological outcomes after induced stroke |
| GHK in cell and database analyses | Gene-expression signatures |
| GHK-Cu on excised human skin | Copper penetration and dermal retention |
| KPV in intestinal cells and mice | Cellular uptake, inflammatory signalling and colitis severity |
The word human can be slippery in this collection. Excised skin is human tissue, and a human cell line has human origins, but neither experimental setting supplies a patient outcome. I distrust a population description that reduces that distinction to a single word.
The untested preparations
The TB-500 fragment has no completed controlled human trial; its parent protein has a separate clinical record. KPV has no published human clinical trial. Wolverine, GLOW and KLOW have no controlled combination study in the published research. The 2026 review describes the larger problem of sparse human safety data among unapproved musculoskeletal peptides.
For BPC-157, TB-500, GHK-Cu and KPV, I want studies in clearly described patient groups, specifying the substance and route throughout. The blend page adds the question of how ingredients behave together. The next useful experiment would name the population its claim is meant to reach and test the exact preparation there.